Metallo Nucleosides: Gold Complexes with Antimetabolite Ligands

金属核苷：与抗代谢配体的金配合物

• 批准号: 409903581
• 负责人: Professor Dr. Ingo Ott
• 金额: --
• 依托单位: Laboratory of Algebra and Number Theory Petersburg
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/409903581?language=en
• 关键词: Metallo; Nucleosides; Gold; Complexes; Antimetabolite

Gold has been playing an important role in medicine tracing back thousands of years. Recently, the interest in gold complexes therapeutic drugs has come to new life as exemplified by several ongoing clinical trials on the lead compound Auranofin. However, the biggest challenges of the approved gold drugs are related to their insufficient chemical and metabolic stability as well as to their low selectivity. This project aims at the design of new gold anticancer metallodrugs, which could overcome these major limitations. The new agents contain nucleoside and carbohydrate moieties to facilitate targeting and to improve the antiproliferative potency. The project will be performed in form of a bilateral collaboration between German and Russian scientists. The new compounds will be subjected to a detailed chemical and biological investigation making use of the complementary research expertise of both partners. Selected promising lead candidates will be studied further in-vivo and provide the basis for a possible future translation into application.

黄金在医学中发挥着重要作用，可以追溯到几千年前。最近，对金络合物治疗药物的兴趣已经获得了新的生命，例如正在进行的几项关于先导化合物金诺芬的临床试验。然而，已批准的黄金药物的最大挑战与其化学和代谢稳定性不足以及选择性低有关。本项目旨在设计新的金抗癌金属药物，可以克服这些主要限制。新的药物含有核苷和碳水化合物部分，以促进靶向和提高抗增殖效力。该项目将以德国和俄罗斯科学家之间的双边合作形式进行。新化合物将利用双方互补的研究专长进行详细的化学和生物学研究。选定的有前途的铅候选人将在体内进一步研究，并提供一个可能的未来转化为应用的基础。